The FDA has granted Fast Track designation to Cardiff Oncology’s investigational drug onvansertib, in combination with FOLFIRI and bevacizumab, for the first-line treatment of adults with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC). The designation is supported by results from the company’s ongoing randomized Phase 2 CRDF-004 trial.
According to the company, the proposed Phase 3 regimen of 30 mg onvansertib achieved a confirmed objective response rate of 72.2%, compared with 42.1% for FOLFIRI and bevacizumab alone in the intent-to-treat population. As of September 28, 2026, median progression-free survival had not been reached in the 30 mg treatment arm, compared with approximately 11 months across the combined standard-of-care arms.
Onvansertib is an oral PLK1 inhibitor. FDA Fast Track designation is intended to facilitate drug development for serious conditions with unmet medical needs. It may provide more frequent FDA interactions and potential eligibility for Accelerated Approval and Priority Review, but does not mean the drug is approved or change the standards required for approval.

